急性冠脉综合征药物干预策略经济学评析综述  

Pharmacoeconomics Analysis on Pharmacotherapy of Acute Coronary Syndromes

作　　者：陈平钰[1] 马爱霞[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国药物评价》2014年第3期189-192,共4页Chinese Journal of Drug Evaluation

摘　　要：通过查阅国内外相关文献,对急性冠脉综合征药物干预策略进行综合评析,综述急性冠脉综合征药物干预策略的药物经济学评价结果,得出具有成本-效果优势的药物干预策略,但仍需进一步深入研究。The pharmacoeconomics research literatures were searched and collected , and which were then evaluated systematically to summarize the pharmacoeconomics evaluation results of acute coronary syndromes pharmacotherapy .Some cost-saving pharmacotherapies are given, but further study is needed.

关 键 词：急性冠脉综合征 药物经济学 综述 

分 类 号：R541.4[医药卫生—心血管疾病]